AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biovitrum licensing agreement with GlaxoSmithKline.
(From Chemical Business NewsBase - Kemivarlden)
Biovitrum has signed an agreement with GlaxoSmithKline to develop and commercialize Biovitrum's substances for the treatment of obesity and other diseases. The collaboration concerns 5-HT2c receptor agonists. The most advanced of these is BVT.933, an appetite inhibitor which has been developed to Phase II by Biovitrum. GlaxoSmithKline will develop, register, manufacture, and commercialize Biovitrum's patented 5-HT2c receptor agonists. Biovitrum will retain the rights in the …
-
- GlaxoSmithKline and Biovitrum Enter Collaboration On Therapies for Obesity...
-
News wire article from: Europe Intelligence Wire
October 23, 2002
700+ words
-
- GlaxoSmithKline and Biovitrum enter collaboration on therapies for obesity...
-
News wire article from: Asia Africa Intelligence Wire
October 23, 2002
700+ words
-
- Biovitrum and GlaxoSmithKline collaborate in antiobesity drug development.
-
News wire article from: Asia Africa Intelligence Wire
October 24, 2002
700+ words
-
- GlaxoSmithKline teams with Biovitrum on obesity drug development.(Brief Article)
-
Newspaper article from: M2 Europharma
October 30, 2002
700+ words
-
- Biovitrum and GlaxoSmithKline to focus efforts on developing highly selective...
-
News wire article from: Europe Intelligence Wire
May 22, 2003
700+ words
